Research programme: anti-HIV monoclonal antibodies - Theraclone Sciences

Drug Profile

Research programme: anti-HIV monoclonal antibodies - Theraclone Sciences

Alternative Names: PGT 121

Latest Information Update: 14 Nov 2016

Price : $50

At a glance

  • Originator Theraclone Sciences
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical HIV infections

Most Recent Events

  • 07 Nov 2016 International AIDS Vaccine Initiative plans a phase I trial in HIV-infections in USA (NCT02960581)
  • 30 Jul 2014 Research programme: anti-HIV monoclonal antibodies - Theraclone Sciences licensed to Gilead Sciences
  • 04 Nov 2013 Research programme: anti-HIV monoclonal antibodies - Theraclone Sciences is available for licensing as of 04 Nov 2013. http://www.theraclone-sciences.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top